Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Moshe Talpaz

Showing results (141-150 of 264) with videos related to

Pageof 27
Sort By:
Blood|April 9, 2004
High-dose imatinib mesylate therapy in newly diagnosed Philadelphia chromosome-positive chronic phase chronic myeloid leukemiaHagop Kantarjian, Moshe Talpaz, Susan O'Brien, et al.
Cell Death & Disease|March 10, 2026
Small molecule screening identifies cytotoxic endoplasmic reticulum-associated degradation inhibitors in multiple myelomaErin M Kropp, Sho Matono, Olivia Y Wang, et al.
Blood Advances|October 4, 2021
Type 1 interferon to prevent leukemia relapse after allogeneic transplantationJohn M Magenau, Dan Peltier, Mary Riwes, et al.
British Journal of Haematology|April 27, 2022
Safety and efficacy of fedratinib, a selective oral inhibitor of Janus kinase-2 (JAK2), in patients with myelofibrosis and low pretreatment platelet countsClaire N Harrison, Nicolaas Schaap, Alessandro M Vannucchi, et al.
Leukemia & Lymphoma|September 21, 2018
Predictive models for splenic response to JAK-inhibitor therapy in patients with myelofibrosisKamal Menghrajani, Philip S Boonstra, Jessica A Mercer, et al.
Blood|December 2, 2004
Imatinib mesylate therapy may overcome the poor prognostic significance of deletions of derivative chromosome 9 in patients with chronic myelogenous leukemiaAlfonso Quintas-Cardama, Hagop Kantarjian, Moshe Talpaz, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|February 22, 2011
NCCN Task Force report: tyrosine kinase inhibitor therapy selection in the management of patients with chronic myelogenous leukemiaSusan O'Brien, Ellin Berman, Joseph O Moore, et al.
Blood|May 3, 2002
Imatinib mesylate (STI571) therapy for Philadelphia chromosome-positive chronic myelogenous leukemia in blast phaseHagop M Kantarjian, Jorge Cortes, Susan O'Brien, et al.
Leukemia Research|June 17, 2018
The FOSSIL Study: FLAG or standard 7+3 induction therapy in secondary acute myeloid leukemiaVera Vulaj, Anthony J Perissinotti, James R Uebel, et al.
Cancer|July 25, 2003
Results of decitabine (5-aza-2'deoxycytidine) therapy in 130 patients with chronic myelogenous leukemiaHagop M Kantarjian, Susan O'Brien, Jorge Cortes, et al.
Pageof 27

Showing results (141-150 of 264) with videos related to

Sort By:
Pageof 27
Blood|April 9, 2004
High-dose imatinib mesylate therapy in newly diagnosed Philadelphia chromosome-positive chronic phase chronic myeloid leukemiaHagop Kantarjian, Moshe Talpaz, Susan O'Brien, et al.
Cell Death & Disease|March 10, 2026
Small molecule screening identifies cytotoxic endoplasmic reticulum-associated degradation inhibitors in multiple myelomaErin M Kropp, Sho Matono, Olivia Y Wang, et al.
Blood Advances|October 4, 2021
Type 1 interferon to prevent leukemia relapse after allogeneic transplantationJohn M Magenau, Dan Peltier, Mary Riwes, et al.
British Journal of Haematology|April 27, 2022
Safety and efficacy of fedratinib, a selective oral inhibitor of Janus kinase-2 (JAK2), in patients with myelofibrosis and low pretreatment platelet countsClaire N Harrison, Nicolaas Schaap, Alessandro M Vannucchi, et al.
Leukemia & Lymphoma|September 21, 2018
Predictive models for splenic response to JAK-inhibitor therapy in patients with myelofibrosisKamal Menghrajani, Philip S Boonstra, Jessica A Mercer, et al.
Blood|December 2, 2004
Imatinib mesylate therapy may overcome the poor prognostic significance of deletions of derivative chromosome 9 in patients with chronic myelogenous leukemiaAlfonso Quintas-Cardama, Hagop Kantarjian, Moshe Talpaz, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|February 22, 2011
NCCN Task Force report: tyrosine kinase inhibitor therapy selection in the management of patients with chronic myelogenous leukemiaSusan O'Brien, Ellin Berman, Joseph O Moore, et al.
Blood|May 3, 2002
Imatinib mesylate (STI571) therapy for Philadelphia chromosome-positive chronic myelogenous leukemia in blast phaseHagop M Kantarjian, Jorge Cortes, Susan O'Brien, et al.
Leukemia Research|June 17, 2018
The FOSSIL Study: FLAG or standard 7+3 induction therapy in secondary acute myeloid leukemiaVera Vulaj, Anthony J Perissinotti, James R Uebel, et al.
Cancer|July 25, 2003
Results of decitabine (5-aza-2'deoxycytidine) therapy in 130 patients with chronic myelogenous leukemiaHagop M Kantarjian, Susan O'Brien, Jorge Cortes, et al.
Pageof 27